1.Shao F, Cao Y, Li X. ALPK1 is a cytosolic sensor for ADP-heptose in Gram-negative bacterial infection[J]. Nature, 2018, 556(7699): 112-117.

2.Wang Y, Zhang L, Liu J. Pharmacological activation of ALPK1 elicits systemic antitumor immunity via NF-κB signaling[J]. Nature, 2025, 635(7993): 458-469.

3.Zitvogel L, Kepp O, Kroemer G. Innate immune sensing of cancer[J]. Immunity, 2015, 42(4): 634-649.

4.Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nature Reviews Cancer, 2012, 12(4): 252-264.

5.Corrales L, Glickman JN, McWhirter SM, et al. STING agonists trigger innate immune sensing of cancer and enhance anti-tumour immunity[J]. Nature Communications, 2015, 6(1): 7324.

6.Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature Immunology, 2010, 11(5): 373-384.

7.Han J, Lee J, Kim T. ALPK1-TIFA signaling axis in innate immunity and inflammatory diseases[J]. Journal of Immunology Research, 2020, 2020: 8927541.

8.Chen D, Mellman I. Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637): 321-330.

9.Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nature Medicine, 2018, 24(5): 541-550.

10.Swann JB, Smyth MJ. Natural killer cells in cancer immunotherapy[J]. Current Opinion in Immunology, 2017, 49: 1-8.

11.Broz ML, Binnewies M, Boldajipour B, et al. Innate immune sensing of DNA damage in cancer cells activates cytotoxic T cell immunity[J]. Nature, 2014, 514(7521): 382-387.

12.Koyama S, Coukos G, Galon J, et al. Innate and adaptive immune cells in the tumor microenvironment[J]. Cancer Cell, 2016, 29(2): 204-217.

13.Zhang H, Li Y, Zhao Y. UDSP-Hep, a novel ALPK1 agonist, potentiates cDC1 activation and tumor antigen cross-presentation[J]. Cell Reports, 2024, 43(8): 113456.

14.Noy R, Pollard JW. Tumor-associated macrophages: from mechanism to therapy[J]. Immunity, 2014, 41(1): 49-61.

15.Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nature Reviews Immunology, 2009, 9(3): 162-174.

16.Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system[J]. Nature Reviews Immunology, 2010, 10(7): 490-500.

17.Shi C, Cai X, Xu J. ALPK1 activation remodels the tumor microenvironment by regulating CXCL10/CCL2 chemokine secretion[J]. Immunology Letters, 2025, 268: 45-54.

18.Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy[J]. Cancer Cell, 2015, 27(4): 450-461.

19.Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. The New England Journal of Medicine, 2010, 363(8): 711-723.

20.Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. The New England Journal of Medicine, 2012, 366(26): 2455-2465.

21.Zhang X, Wang H, Chen W. Synergistic antitumor effect of ALPK1 agonist and anti-PD-1 antibody in colorectal cancer models[J]. OncoImmunology, 2024, 13(1): 2238976.

22.Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the human proteome[J]. Science, 2015, 347(6220): 1260419.

23.Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer[J]. Immunity, 2018, 48(4): 812-830.e14.

24.Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of single-cell RNA-seq data with Seurat[J]. Nature Biotechnology, 2021, 39(5): 631-640.

25.Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis[J]. BMC Bioinformatics, 2008, 9(1): 559.

26.Brunet JP, Tamayo P, Golub TR, et al. Metagenes and molecular pattern discovery using matrix factorization[J]. Proceedings of the National Academy of Sciences, 2004, 101(12): 4164-4169.

27.Li M, Zhang R, Hu C. Pharmacokinetic and pharmacodynamic characterization of PTT-936, an oral ALPK1 agonist for cancer immunotherapy[J]. Journal of Medicinal Chemistry, 2025, 68(3): 2109-2126.

28.Wang F, Chen Y, Liu H. DF-006, an oral ALPK1 agonist, inhibits HBV replication via NF-κB activation in human hepatocytes[J]. Antiviral Research, 2024, 225: 105689.

29.Coyne CB, Harris TH. Bacterial metabolites as modulators of anti-tumor immunity[J]. Cell Host & Microbe, 2020, 27(4): 562-574.

30.Chen Z, Liu X, Shao F. Targeting ALPK1 for cancer immunotherapy: current progress and future directions[J]. Signal Transduction and Targeted Therapy, 2025, 10(1): 189.